Royalty Pharma

RPRX

Market cap $15.6B

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee.

Royalty Pharma plc (NASDAQ:RPRX ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 2:50 PM EDT Company Participants Marshall Urist - Executive Vice President of Research & Investments Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein's 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.

Royalty Pharma remains a Buy supported by strong execution and upward guidance revision. RPRX trades at a significant valuation discount to biopharma peers, with 86% of its portfolio in approved therapies and robust free cash flow growth. Management projects 11–14% portfolio receipts CAGR through 2030, exceeding consensus, and demonstrates disciplined capital allocation with M&A capability.

Royalty Pharma plc (NASDAQ:RPRX ) Investor Day 2025 Conference September 11, 2025 8:30 AM EDT Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman of the Board & CEO Ashwin Pai - Executive Vice President of Investments Christopher Hite - Vice Chairman & Executive VP Brienne Kugler - Senior VP of Research & Investments Marshall Urist - Executive Vice President of Research & Investments Terrance Coyne - Executive VP & CFO Conference Call Participants Christopher Schott - JPMorgan Chase & Co, Research Division Terence Flynn - Morgan Stanley, Research Division Dina Ramadane - BofA Securities, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Ivan Feinseth - Tigress Financial Partners LLC, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Ashwani Verma - UBS Investment Bank, Research Division Michael Nedelcovych - TD Cowen, Research Division Phillip Gross - Adage Capital Management, L.P. Paul Kuhn - TD Cowen, Research Division Presentation George Grofik Senior VP and Head of Investor Relations & Communications Good morning, everyone.

On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma's platform value Investments since 2020 on track to deliver mid-teens unlevered IRR, ahead of target Achieved 15% Return on Invested Capital (ROIC) and 21% Return on Invested Equity (ROIE) since 2019 Royalty market continues to grow rapidly, doubling over five years since Royalty Pharma's 2020 IPO Strong industry tailwinds and demand for royalty funding supported by Deloitte market study report NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today.

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlook for biopharma royalties. The full report is available for download at Deloitte's website and Royalty Pharma's website.